Myocardial protective effect of L-carnitine in children with hand, foot and mouth disease caused by Coxsackie A16 virus

• Published in: Zhongguo dang dai er ke za zhi Vol. 19; no. 8; pp. 908 - 912
• Main Authors: Cui, Ya-Jie, Song, Chun-Lan, Chen, Fang, Li, Peng, Cheng, Yi-Bing
• Format: Journal Article
• Language: Chinese
• Published: China 01.08.2017
• Subjects: Carnitine - therapeutic use; Child, Preschool; Coxsackievirus Infections - complications; Female; Hand, Foot and Mouth Disease - drug therapy; Hand, Foot and Mouth Disease - etiology; Hand, Foot and Mouth Disease - metabolism; Heart - drug effects; Humans; Infant; Male; Malondialdehyde - analysis; Myocardium - metabolism; Myocardium - pathology; Superoxide Dismutase - metabolism
• ISSN: 1008-8830
• DOI: 10.7499/j.issn.1008-8830.2017.08.012

To investigate the myocardial protective effect of L-carnitine in children with hand, foot and mouth disease (HFMD) caused by Coxsackie A16 virus and possible mechanisms. A total of 60 HFMD children with abnormal myocardial enzyme after Coxsackie A16 virus infection were enrolled and randomly divided into L-carnitine group and fructose-1,6-diphosphate group (fructose group), with 30 children in each group. The two groups were given L-carnitine or fructose diphosphate in addition to antiviral and heat clearance treatment. Another 30 healthy children who underwent physical examination were enrolled as control group. The changes in myocardial zymogram, malondialdehyde (MDA), superoxide dismutase (SOD), and apoptosis factors sFas and sFasL after treatment were compared between groups. There was no significant difference in treatment response between the L-carnitine group and the fructose group (P>0.05). One child in the fructose group progressed to critical HFMD, which was not observed in the L-carnitine group. B